Evaluation of mangafodipir treatment for oxaliplatin-associated neuropathy
(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, Frédéric Batteux and colleagues at the Laboratoire d'Immunologie evaluated use of the MRI contrast agent mangafodipir, which has antioxidant properties, for relief of oxaliplatin-associated neuropathies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2013 Category: Global & Universal Source Type: news
Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer
(European Organisation for Research and Treatment of Cancer) Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1 percent difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. The authors conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for this population of patients. (Source: EurekAlert! -...
Source: EurekAlert! - Medicine and Health - November 6, 2013 Category: Global & Universal Source Type: news
Indication Of Minor Added Benefit For Aflibercept In Colorectal Cancer
Indication of considerable added benefit for overall survival / indications of greater harm from side effects The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 15, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news
Adjuvant Chemo Boosts Survival in Advanced Stomach CancerAdjuvant Chemo Boosts Survival in Advanced Stomach Cancer
Mature data from a phase 3 trial confirm that capecitabine plus oxaliplatin after gastrectomy yields a significant survival advantage over surgery alone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Study confirms adding chemotherapy to surgery improves survival in advanced gastric cancer
(European Society for Medical Oncology) At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-year follow-up from the phase III CLASSIC trial, which added combination chemotherapy to a standard surgical procedure called D2 gastrectomy. The chemotherapy regimen studied in the trial is called XELOX, which is a combination of the drugs capecitabine and oxaliplatin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2013 Category: Global & Universal Source Type: news
Stop Using Calcium and Magnesium With Oxaliplatin Stop Using Calcium and Magnesium With Oxaliplatin
New results have led to call for stopping the practice of administering intravenous calcium and magnesium to reduce oxaliplatin neurotoxicity. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Adding Oxaliplatin to Radiotherapy in Nasopharyngeal CancerAdding Oxaliplatin to Radiotherapy in Nasopharyngeal Cancer
Adding oxaliplatin to radiotherapy (RT) for locoregionally advanced nasopharyngeal carcinoma appears to have lasting survival benefits, according to Chinese researchers. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ZALTRAP® (Aflibercept) Approved In The EU For Patients With Previously Treated Metastatic Colorectal Cancer
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimenSanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 8, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news
ZALTRAP® approved in the EU for metastatic colorectal cancer
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the European Commission (EC) granted marketing authorisation in the European Union for ZALTRAP® (aflibercept) 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 6, 2013 Category: Drugs & Pharmacology Source Type: news
EMA grants marketing authorisation of aflibercept (ZaltrapT) for previously treated metastatic colorectal cancer
Source: BioSpace
Area: News
The European Commission (EC) has granted marketing authorisation for aflibercept (ZaltrapT) for use in combination with irinotecan/ 5-fluorouracil/ folinic acid (FOLFIRI) chemotherapy for the treatment of adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
This decision was based on the efficacy and safety results of the multinational, phase III randomised controlled VELOUR trial (n=1,226). The study showed that in patients previously treated with an oxaliplatin containing regimen, adding aflibercept to FOLF...
Source: NeLM - News - February 6, 2013 Category: Drugs & Pharmacology Source Type: news
FDA Approves Bevacizumab for Second-Line Combinations
Bevacizumab is now approved by the Food and Drug Administration for use in combination with fluoropyrimidine-irinotecan-based or fluoropyrimidine-oxaliplatin-based chemotherapy for metastatic colorectal... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news
FDA approves use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug
Source: Reuters
Area: News
The FDA has approved the use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug. The new use will allow patients first treated with bevacizumab plus chemotherapy to be treated again with it in combination with a different chemotherapy regimen.
The clinical data to support this indication come from the phase 3 ML18147 study in 820 patients with unresectable metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy. They were randomised to second-line chemotherapy with (n= ...
Source: NeLM - News - January 25, 2013 Category: Drugs & Pharmacology Source Type: news
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC). The new indication will allow people who received Avastin plus an irinotecan or oxaliplatin containing chemotherapy as an initial treatment (first-line) for mCRC to continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy after their cancer worsens (second-line treatment). (Source: Roche Investor Update)
Source: Roche Investor Update - January 24, 2013 Category: Pharmaceuticals Source Type: news
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC). The new indication will allow people who received Avastin plus an irinotecan or oxaliplatin containing chemotherapy as an initial treatment (first-line) for mCRC to continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy after their cancer worsens (second-line treatment). (Source: Roche Media News)
Source: Roche Media News - January 24, 2013 Category: Pharmaceuticals Source Type: news
FDA approves colon cancer drug combo
WASHINGTON, Jan. 23 (UPI) -- The U.S. Food and Drug Administration says it approved a new use of Avastin in combination with oxaliplatin chemotherapy for those colorectal cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 24, 2013 Category: Consumer Health News Source Type: news
